Immunotherapy before surgery shows promise for certain colorectal cancers
NCT ID NCT05197322
First seen Apr 24, 2026
Summary
This trial is testing whether giving the immunotherapy drug pembrolizumab before surgery can improve outcomes for people with high-risk stage 2 or stage 3 colorectal cancer that has a specific genetic feature called mismatch repair deficiency. About 88 participants will receive pembrolizumab for up to 9 weeks before their planned surgery. Researchers will track how long patients stay cancer-free and whether the tumor is completely removed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADENOCARCINOMA OF THE COLON are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Addenbrookes Hospital
RECRUITINGCambridge, CB2 0QQ, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Beatson West of Scotland Cancer Centre
RECRUITINGGlasgow, G12 0YN, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Christie Hospital NHS Trust, Wilmslow Road,
RECRUITINGManchester, M20 4BX, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Southampton General Hospital
COMPLETEDSouthampton, SO16 6YD, United Kingdom
-
St James University Hospital (SJUH)
COMPLETEDLeeds, LS9 7TF, United Kingdom
-
University College Hospital
RECRUITINGLondon, NW1 2BU, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pembrolizumab (immunotherapy drug)
What this could lead to
If successful, this could show that giving pembrolizumab before surgery helps remove the tumor completely and delays or prevents cancer from coming back in patients with this specific type of colorectal cancer.
What could go wrong
This is a small Phase 2 trial with only 88 participants, so results may not apply to everyone. Immunotherapy can cause side effects like inflammation in healthy organs, and not all patients may respond.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.